Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Arsenic trioxide and neuroblastoma cytotoxicity.

Författare

Summary, in English

The majority of aggressive forms of the childhood tumor neuroblastoma can with current treatment protocols not be cured and possess a major challenge in pediatric oncology. After initial rounds of chemotherapy, surgery and irradiation, which in most cases result in tumor regression, these aggressive neuroblastomas relapse and frequently develop drug resistance. As approximately 50% of the children with neuroblastoma have an aggressive form, there is a compelling demand for new treatment strategies. Arsenic trioxide has the capacity to kill multidrug-resistant neuro-blastoma cells in vitro and in vivo and the drug is currently being evaluated in clinical trials. In this report we discuss the background to the use of arsenic trioxide in cancer therapy and the currently known mechanisms by which arsenic trioxide kills human neuroblastoma cells.

Publiceringsår

2007

Språk

Engelska

Sidor

35-41

Publikation/Tidskrift/Serie

Journal of Bioenergetics and Biomembranes

Volym

39

Issue

1

Dokumenttyp

Artikel i tidskrift

Förlag

Springer

Ämne

  • Cancer and Oncology
  • Pediatrics

Nyckelord

  • Neuroblastoma
  • Arsenic trioxide
  • Cell death
  • APL
  • Bax

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1573-6881